In the BioHarmony Drug Report Database
Xiidra (lifitegrast) is a small molecule pharmaceutical. Lifitegrast was first approved as Xiidra on 2016-07-11. It is used to treat dry eye syndromes in the USA. The pharmaceutical is active against integrin alpha-L. Xiidra’s patents are valid until 2033-12-18 (FDA).
Image (chem structure or protein)